• Es befinden sich keine Produkte im Warenkorb.


Literatur und weiterführende Links (FOOD 50-51)


Adams JB, Holloway C: Pilot study of a moderate dose multivitamin/mineral supplement for children with autistic spectrum disorder. J Altern Complement Med 2004; 10: 1033-1039.

Afzal S, Bojesen SE, Nordestgaard BG. Reduced 25-hydroxyvitamin D and risk of Alzheimer’s disease and vascular dementia. Alzheimers Dement. 2013 Jul 18.

Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF, Bottiglieri T, Jin S, Stokes KT, Thomas RG, Thal LJ; Alzheimer Disease Cooperative Study. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA. 2008; 300: 1774-83.

Alpert JE, Fava M: Nutrition and depression: the role of folate. Nutr Rev 1997; 55:145-149.

Altamura S, Muckenthaler MU. Iron toxicity in diseases of aging: Alzheimer’s disease, Parkinson’s disease and atherosclerosis. J Alzheimers Dis. 2009; 16: 879-895.

Amerikanische Schlaganfall Gesellschaft (in Englisch) http://strokeassociation.org/ (eingesehen am 11.01.2021)

Amminger PG, Berger GE, Schafer MR et al.: Omega-3 fatty acids supplementation in children with Autism: A double-blind randomized, placebo-controlled pilot study. Biol. Psychiatry 2007; 61: 551-553.

Andreassen OA, Dedeoglu A, Ferrante RJ, Jenkins BG, Ferrante KL, Thomas M, Friedlich A, Browne SE, Schilling G, Borchelt DR, Hersch SM, Ross CA, Beal, MF. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington’s disease. Neurobiol. Dis. 2001;8, 479–491.

Andres-Lacueva C, Shukitt-Hale B, Galli RL et al. Anthocyanins in aged blueberry-fed rats are found centrally and may enhance memory. Nutr Neurosci 2005; 8: 111–120.

Arvindakshan M, Ghate M, Ranjekar PK et al. Supplementation with a combination of ω-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr Res 2003; 62: 195–204.

Aschner M, Aschner JL. Manganese neurotoxicity: Cellular effects and blood-brain barrier transport. Neurosci Biobehav Rev 1991; 15: 333–340.

Aschner M, Erikson KM, Dorman DC. Manganese dosimetry: Species differences and implications for neurotoxicity. Crit Rev Toxicol 2005; 35: 1–32.

Ashtari F, Ajalli M, Shaygannejad V, Akbari M, Hovsepian S. The relation between Vitamin D status with fatigue and depressive symptoms of multiple sclerosis. J Res Med Sci. 2013;18: 193-7.

Bademosi O, Osuntokun BO. Diseases of peripheral nerves as seen in the Nigerian African. Afr J Med Med Sci 1981; 10:33.

Balk EM, Raman G, Tatsioni A, Chung M, Lau J, Rosenberg IH. Vitamin B6, B12, and folic acid supplementation and cognitive function: a systematic review of randomized trials. Arch Intern Med. 2007;167: 21-30.

Barbiroli B, Montagna P, Cortelli P, et al. Abnormal brain and muscle energy metabolism shown by31P magnetic resonancespectroscopy innpatients affected by migraine with aura. Neurology. 1992; 42: 1209–1214.

Bardhan J, Chakraborty R, Raychaudhuri U. The 21st century form of vitamin E-tocotrienol. Curr Pharm Des. 2011; 17: 2196-205.

Baum L, Lam CW, Cheung SK, et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol. 2008; 28: 110-113.

Beal FM: Cell death by oxidants: neuroprotective antioxidant therapies. Abstract presented at the Fourth International Nice/Springfield Symposium on Advances in Alzheimer Therapy, France: Nice; 1996.

Belkacemi A, Doggui S, Dao L, Ramassamy C. Challenges associated with curcumin therapy in Alzheimer disease. Expert Rev Mol Med 2011; 13: e34.

Benarroch EE. Brain iron homeostasis and neurodegenerative disease. Neurology. 2009; 72: 1436-1440.

Bender A, Auer DP, Merl T, Reilmann R, Saemann P, Yassouridis A, Bender J, Weindl A, Dose M, Gasser T, Klopstock T. Creatine supplementation lowers brain glutamate levels in Huntington’s disease. J. Neurol. 2005; 252, 36–41.

Benton D, Cook R. The impact of selenium supplementation on mood. Biol Psychiatry 1991; 29: 1092–1098.

Benton D, Donohoe RT. The effects of nutri­ents on mood. Public Health Nutr 1999; 2 (3A): 403–409.

Benton D. Micro-nutrient supplementation and the intelligence of children. Neurosci Biobehav Rev. 2001; 25: 297–309.

Benton D. Selenium intake, mood and other aspects of psychological functioning. Nutr Neurosci 2002; 5: 363–374.

Benton D. The influence of dietary status on the cognitive performance of children. Mol Nutr Food Res. 2010; 54: 457–470.

Berlit P. Klinische Neurologie. Springer Verlag 2006, S. 430.

Beydoun MA, Beydoun HA, Wang Y. Obe­sity and central obesity as risk factors for inci­dent dementia and its subtypes: a systematic re­view and meta-analysis. Obes Rev 2008; 9: 204–218.

Bigal, M.E.: Obesity and migraine. A population study. Neurology 2006; 66: 545–550.

Bitarafan S, Harirchian MH, Sahraian MA, Keramatipour M, Beladi Moghadam N, Togha M, Nafissi S, Siassi F, Eshraghian MR, Mohammadzadeh Honarvar N, Ansar H, Talebi S, Saboor-Yarghi AA. Impact of Vitamin A Supplementation on RAR Gene Expression in Multiple Sclerosis Patients. J Mol Neurosci. 2013; 51: 478-84.

Bodnar LM, Wisner KL. Nutrition and De­pression: Implications for improving mental health among childbearing-aged women. Biol Psychiatry 2005; 58: 679–685.

Boehnke C, Reuter U, Flach U, et al. High-dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre. Eur J Neurol. 2004; 11: 475–477.

Boldt DH. New perspectives on iron: An introduction. Am J Med Sci 1999; 318: 207–212.

Bölte S, Poustka F. The German form of the autism diagnostic observation schedule (ADOS): first results on reliability and validity. Z Kinder Jugendpsychiatr Psychother 2004; 32: 45–50.

Bottiglieri T, Laundy M, Crellin R, et al: Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry 2000; 69: 228-232.

Boucher BJ. The problems of vitamin d insufficiency in older people. Aging Dis. 2012; 3: 313-29.

Bourre JM. Effects of nutrients (in food) on the structure and function of the nervous system: Update on Dietary Requirements for Brain. Part 2: Macronutrients. J Nutr Health Aging 2006; 10: 386–399.

Brenner SR. Mitochondrial DNA haplogroups influence the therapeutic response to riboflavin in migraineurs. Neurology. 2010; 74: 182-3.

Brewer GJ. Copper in medicine. Curr Opin Chem Biol 2003; 7: 207–212.

Brinkworth GD, Buckley JD, Noakes M et al. Long-term effects of a very low-carbohy­drate diet and a low-fat diet on mood and cog­nitive function. Arch Intern Med 2009; 169: 1873–1880.

Bronisch, F.W.: Multiple Sklerose. Enke, Stuttgart 1975.

Bronner LL, Kanter DS, Manson JE. Pri­mary prevention of stroke. N Engl J Med 1995; 333:1392–1400.

Bruijn J, Duivenvoorden H, Passchier J, Locher H, Dijkstra N, Arts WF. Medium-dose riboflavin as a prophylactic agent in children with migraine: a preliminary placebo-controlled, randomised, double-blind, cross-over trial. Cephalalgia. 2010; 30: 1426-34.

Bruinsma KA, Taren DL: Dieting, essential fatty acid intake, and depression. Nutr Rev 2000; 58: 98-108.

Bryan J, Calvaresi E, Hughes D. Short-term folate, vitamin B-12 or vitamin B-6 supplementation slightly affects memory performance but not mood in women of various ages. J Nutr. 2002; 132: 1345-1356.

Bryan J, Osendarp S, Hughes D, et al. Nutrients for cognitive development in school-aged children. Nutr Rev. 2004; 62: 295–306.

Buell JS, Tucker KL. The value of physiologic vitamin D as a biomarker of dementia. Drugs Today (Barc). 2011; 47: 223-31.

Bunker VW, Lawson MS, Stansfield MF, Clayton BE. Selenium balance studies in apparently healthy and housebound elderly people eating self-selected diets. Br J Nutr 1988; 59:171–180.

Cacciapuoti F. Lowering homocysteine levels with folic acid and B-vitamins do not reduce early atherosclerosis, but could interfere with cognitive decline and Alzheimer’s disease. J Thromb Thrombolysis. 2013; 36: 258-62.

Campbell D, Bunker VW, Thomas AJ, Clayton BE. Selenium and vitamin E status of healthy and institutionalized elderly subjects: Analysis of plasma, erythrocytes and platelets. Br J Nutr 1989; 62: 221–227.

Carrter CM, Egger J, Soothill JF: Dietary management of severe childhood migraine. Hum Nutr: Appl Nutr 1985; 39 A: 294–303.

Carta A, Calvani M, Bravi D, Bhuachalla SN. Acetyl-L-carnitine and Alzheimer’s disease: pharmacological considerations beyond the cholinergic sphere. Ann N Y Acad Sci 1993; 695: 324-326.

Caspi A, Moffitt TE. Gene-environment interactions in psychiatry: joining forces with neuroscience. Nat Rev Neurosci 2006; 7: 583–590.

Castano A, Ayala A, Rodriguez-Gomez JA, Herrera AJ, Cano J, Machado A. Low selenium diet increases the dopamine turnover in prefrontal cortex of the rat. Neurochem Int 1997; 30: 549–555.

Chan A, Paskavitz J, Remington R, Rasmussen S, Shea TB. Efficacy of a vitamin/nutraceutical formulation for early-stage Alzheimer’s disease: a 1-year, open-label pilot study with an 16-month caregiver extension. Am J Alzheimer’s Dis Other Demen 2009; 23: 571–585.

Chan A, Remington R, Kotyla E, Lepore A, Zemianek J, Shea TB. A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia. J Nutr Health Aging 2010; 14: 224–230.

Chaves LC, Faintuch J, Kahwage S, Alencar Fde A. A cluster of polyneuropathy and Wernicke-Korsakoff syndrome in a bariatric unit. Obes Surg 2002; 12: 328.

Chayasirisobhon S. Efficacy of Pinus radiata bark extract and vitamin C combination product as a prophylactic therapy for recalcitrant migraine and long-term results. Acta Neurol Taiwan. 2013; 22: 13-21.

Chiu CC, Su KP, Cheng TC et al. The effects of omega-3 fatty acids monotherapy in Alzhei­mer’s disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1538–1544.

Chiu HY, Tsai PS, Lee CC, Liu YT, Huang HC, Chen PY. The association between use of dietary Supplements and Headache or Migraine Complaints. Headache. 2013 Jul 12.

Christensen L, Somers S: Comparison of nutrient intake among depressed and nondepressed individuals. Int J Eat Disord 1996; 20:105-109.

Chua AC, Morgan EH. Effects of iron deficiency and iron overload on manganese uptake and deposition in the brain and other organs of the rat. Biol Trace Elem Res 1996; 55: 39–54.

Clair, D.S., M. Xu, P. Wang, Y. Yu, Y. Fang: Rates of adult schizophrenia following prenatal exposure to the Chinese famine of 1959–1961. JAMA 2005; 294: 557–562.

Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol. 1998;55:1449-1455.

Commenges D, Scotet V, Renaud S et al. Intake of flavonoids and risk of dementia. Eur J Epidemiol 2000; 16: 357–363.

Condò M, Posar A, Arbizzani A, Parmeggiani A. Riboflavin prophylaxis in pediatric and adolescent migraine. J Headache Pain. 2009; 10: 361-5.

Connor WE, Connor SL: The importance of fish and docosahexaenoic acid in Alzheimer disease. Am J Clin Nutr 2007; 85: 929–930.

Conquer J, Tierney M, Zecevic J, Bettger W, Fisher R. Fatty acid analysis of blood plasma of patients with Alzheimer’s disease, other types of dementia, and cognitive impairment. Lipids 2000; 35: 1305–1312.

Cooper JM, Korlipara LV, Hart PE, Bradley JL, Schapira AH. Coenzyme Q10 and vitamin E deficiency in Friedreich’s ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy. Eur J Neurol. 2008;15:1371-9.

Cordero MD, Cano-García FJ, Alcocer-Gómez E, De Miguel M, Sánchez-Alcázar JA. Oxidative stress correlates with headache symptoms in fibromyalgia: coenzyme Q10 effect on clinical improvement. PLoS One. 2012; 7: e35677.

Cornett CR, Markesbery WR, Ehmann WD. Imbalances of trace elements related to oxidative damage in Alzheimer’s disease brain. Neurotoxicology 1998; 19: 339–345.

Correale J. If I had clinically isolated syndrome with magnetic resonance imaging diagnostic of multiple sclerosis, I would take vitamin D 10,000 IU daily: Yes. Mult Scler. 2013; 19:137-9.

Corrigan FM, Horrobin DF, Skinner ER, Besson JAO, Cooper MB. Abnormal content of n − 6 and n − 3 long-chain unsaturated fatty acids in the phosphoglycerides and cholesterol esters of parahippocampal cortex from Alzheimer’s disease patients and its relationship to acetyl CoA content. Int J Biochem Cell Biol 1998; 30: 197–207.

Couturier EGM, Hering R, Steiner TJ: Weekend attacks in migraine patients: Caused by caffeine withdrawal? Cephalalgie 1992; 12: 99–100.

Critchfield WJ, Hemert S, Ash M et al.: The potential role of probiotics in the management of childhood Autism Spectrum Disorders. Gastroenterol. Res. Pract. 2011; 1-8.

Crossgrove J, Zheng W. Manganese toxicity upon overexposure. NMR Biomed 2004; 17: 544–553.

Cuajungco MP, Faget KY. Zinc takes the center stage: Its paradoxical role in Alzheimer’s disease. Brain Res Brain Res Rev 2003; 41: 44–56.

da Silva FL, Coelho Cerqueira E, de Freitas MS, Gonçalves DL, Costa LT, Follmer C. Vitamins K interact with N-terminus α-synuclein and modulate the protein fibrillization in vitro. Exploring the interaction between quinones and α-synuclein. Neurochem Int. 2013; 62: 103-12.

Dalton K, Dalton MJ. Characteristics of pyridoxine overdose neuropathy syndrome. Acta Neurol Scand. 1987; 76: 8-11.

De Caterina R, Zampolli A, Del Turco S et al. Nutritional mechanisms that influ­ence cardiovascular disease. Am J Clin Nutr 2006; 83: 421S–426S.

Deijen JB, van der Beek EJ, Orlebeke JF, van den Berg H. Vitamin B-6 supplementation in elderly men: effects on mood, memory, performance and mental effort. Psychopharmacology . 1992;109: 489-496.

Dellon AL, Dellon ES, Tassler PL, et al. Experimental model of pyridoxine (B6) deficiency-induced neuropathy. Ann Plast Surg 2001; 47: 153.

Deutsche Gesellschaft für Neurologie: http://www.dgn.org/ (eingesehen am 07.09.2023)

DiFrancisco-Donoghue J, Lamberg EM, Rabin E, Elokda A, Fazzini E, Werner WG. Effects of exercise and B vitamins on homocysteine and glutathione in Parkinson’s disease: a randomized trial. Neurodegener Dis. 2012; 10: 127-34.

DiGirolamo AM, Ramirez-Zea M, Wang M, et al. Randomized trial of the effect of zinc supplementation on the mental health of school-age children in Guatemala. Am J Clin Nutr. 2010; 92: 1241–1250.

Dionne G, Boivin M, Seguin JR et al.: Gestational diabetes hinders language development in offspring. Pediatrics 2008; 122: 1073-1079.

Dolske MC, Spollen J, McKay S et al: A preliminary trial of ascorbic acid as supplemental therapy for autism. Prog Neuropsychopharmacol Biol Psychiatry 1993; 17: 765-774.

Dosman CF, Brian JA, Drmic IE et al.: Children with Autism: effect of iron supplementation on sleep and ferritin. Dev. Med. Child Neurol. 2006; 48: 1006-1011.

Dusek P, Jankovic J, Le W. Iron dysregulation in movement disorders. Neurobiol Dis 2012; 46:1-18.

Dworkin RH, Bates D, Millar JHD, Paty DW: Linoleic acid and multiple sclerosis: a re-analysis of three double blind trials. Neurology 1984; 34: 1441–1445.

Ebly EM, Schaefer JP, Campbell NR, Hogan DB. Folate status, vascular disease and cognition in elderly Canadians. Age Ageing. 1998; 27: 485-491.

Egger J, Carter CM, Soothill JF, Wilson J: Oligoantigenic diet treatment of children with epilepsy and migraine. J Pediatr 1989; 114: 51–58.

Engelhart M, Geerlings M, Ruitenberg A, van Swieten J, Holman A, Witteman J. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 2002; 287: 3223–3229.

Engelhart MJ, Geerlings MI, Ruitenberg A et al. Diet and risk of dementia: Does fat matter? The Rotterdam Study. Neurology 2002; 59: 1915–1921.

Eussen SJ, de Groot LC, Joosten LW, et al. Effect of oral vitamin B-12 with or without folic acid on cognitive function in older people with mild vitamin B-12 deficiency: a randomized, placebo-controlled trial. Am J Clin Nutr. 2006; 84: 361-370.

Eyles DW, Cui X, Kesby JP et al.: Developmental vitamin D deficiency causes abnormal brain development. J. Psyneuen. 2009; 345: 247-257.

Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ: Distribution of the vitamin D receptor and 1a-hydroxylase in human brain. J Chem Neuroanat, 2005, 29, 21–30.

Fahn SA: A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson’s disease. Ann Neurol 1992; 32: 128–132.

Fava M, Mischoulon D: Folate in depression: efficacy, safety, differences in formulations, and clinical issues. J Clin Psychiatry 2009; 5: 12-17.

Feinstein L, Sabates R, Sorhaindo A, et al. Dietary patterns related to attainment in school: the importance of early eating patterns. J Epidemiol Community Health. 2008; 62: 734–739.

Ferland G. Vitamin K, an emerging nutrient in brain function. Biofactors. 2012; 38: 151-7.

Ferrante RJ, Andreassen OA, Dedeoglu A, Ferrante KL, Jenkins BG, Hersch SM and Beal MF. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington’s disease. J. Neurosci. 2002; 22, 1592–1599.

Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M. Alzheimer’s Disease International. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005; 366: 2112-7.

Forette F, Seux ML, Staessen JA et al. Prevention of dementia in randomised double-blind place­bo-controlled systolic hypertensi­on in Europe (Syst-Eur) trial. Lancet 1998; 352: 1347–1351.

Francis PT. Glutamatergic systems in Alzheimer’s disease. Int J Geriatr Psychiatry. 2003; 18: S. 15-21.

Frautschy SA, Hu W, Kim P, et al. Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. Neurobiol Aging. 2001; 22: 993-1005.

Freitag CM. The genetics of autistic disorders. Z Kinder Jugendpsychiatr Psychother 2008; 36: 7–14.

Freund-Levi Y, Eriksdotter-Jönhagen M, Cede­rholm T et al. Omega-3 fatty acid treat­ment in 174 patients with mild to moderate Alz­heimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 2006; 63: 1402–1408.

Galazka-Friedman J, Bauminger ER, Friedman A. Iron in parkinsonian and control substantia nigra: a Mossbaur spectroscopy study. Mov Disord 1996; 11: 8-16.

Gerlach M, Ben-Shachar D, Riederer P, Youdim MB. Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 1994; 63: 793–807.

Ghazavi A, Kianbakht S, Ghasami K, Mosayebi G. High copper and low zinc serum levels in Iranian patients with multiple sclerosis: a case control study. Clin Lab. 2012; 58: 161-4.

Gilliland K, Bullock W: Caffeine: a potential drug of abuse. Adv Alcohol Subst Abuse 1983; 3: 53-73.

GISSI-Prevenzione Investigators: Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999; 354: 447–455.

Glaso M, Nordbo G, Diep L, Bohmer T. Reduced concentrations of several vitamins in normal weight patients with late-onset dementia of the Alzheimer type without vascular disease. J Nutr Health Aging. 2004; 8: 407-413.

Goff DC, Bottiglieri T, Arning E et al. Folate, homocysteine, and negative symptoms in schizo­phrenia. Am J Psychiatry 2004; 161: 1705–1708.

Goldust M, Taheraghdam A, Talebi M, Farhoudi M, Majidi J. Evaluation of iron serum level in Alzheimer disease. J Pak Med Assoc. 2013; 63: 300.

Gomez-Pinilla F. Brain foods: the effects of nutrients on brain function. Nat Rev Neurosci 2008; 9: 568–578.

Gonzalez S, Huerta JM, Alvarez-Uria J, Fernandez S, Patterson AM, Lasheras C. Serum selenium is associated with plasma homocysteine concentrations in elderly humans. J Nutr 2004; 134: 1736–1740.

Goodwin FK: Alcoholism research: delivering on the promise. Public Health Rep 1988; 103: 569-574.

Grant WB, Soles CM: Epidemiologic evidence supporting the role of maternal vitamin D deficiency as a risk factor for the development of infantile autism. Derm. Endocrinol. 2009; 4: 223-228.

Grant WB. Vitamin D might reduce some vascular risk factors and, consequently, risk of dementia. Neth J Med. 2011; 69: 51.

Grant WB: Dietary links to Alzheimer’s disease. Alzheimer Dis Rev 1997; 2: 42-45.

Greger JL. Nutrition versus toxicology of manganese in humans: Evaluation of potential biomarkers. Neurotoxicology 1999; 20: 205–212.

Griffiths PD, Dobson BR, Jones GR, Clarke DT. Iron in the basal ganglia in Parkinson’s disease. An in vitro study using extended Xray absorption fine structure and cryo-electron microscopy. Brain 1999; 122 (Pt 4): 667–673.

Group HS. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington’s disease. Neurology 2001; 57,397–404.

Guggenheim MA, Ringel SP, Silverman A, Grabert BE. Progressive neuromuscular disease in children with chronic cholestasis and vitamin E deficiency: diagnosis and treatment with alpha tocopherol. J Pediatr 1982; 100: 51.

Hadjivassiliou M, Grünewald RA, Lawden M, Davies-Jones GAB, Powell T, Smith CML. Headache and CNS white matter abnormalities associated with gluten sensitivity. Neurology 2001; 56: 385–388.

Haghdoost-Yazdi H, Fraidouni N, Faraji A, Jahanihashemi H, Sarookhani M. High intake of folic acid or complex of B vitamins provides anti-Parkinsonism effect: no role for serum level of homocysteine. Behav Brain Res. 2012; 233: 375-81.

HaMai D, Bondy SC. Oxidative basis of manganese neurotoxicity. Ann NY Acad Sci 2004; 1012: 129–141.

Hanington E.: Migraine. In: Lessof, M.H.: Clinical reactions to food. Wiley & Sons 1983.

Harms LR, Burne TH, Eyles DW, McGrath JJ: Vitamin D and the brain. Best Pract Res Clin Endocrinol Metab, 2011; 25: 657–669.

Harper CG, Giles M, Finlay-Jones R. Clinical signs in the Wernicke-Korsakoff complex: a retrospective analysis of 131 cases diagnosed at necropsy. J Neurol Neurosurg Psychiatry 1986; 49: 341–345.

Hawkes WC, Hornbostel L. Effects of dietary selenium on mood in healthy men living in a metabolic research unit. Biol Psychiatry 1996; 39:121–128.

Heilbronn LK, Jonge L de, Frisard MI et al Pen­nington CALERIE Team. Effect of 6-month calorie restriction on biomarkers of longevi­ty, metabolic adaptation, and oxidative stress in overweight individuals: a randomized controlled trial. JAMA 2006; 295: 1539–1548.

Hendrie HC, Hall KS, Ogunniyi A, Gao S. Alzheimer’s disease, genes, and microenviron­ment: the value of international studies. Can J Psychiatry 2004; 49: 92–99.

Hendrie HC, Ogunniyi A, Hall KS et al. In­cidence of dementia and Alzheimer disease in 2 communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana. JAMA 2004; 295: 1539–1548.

Hendrie HC, Ogunniyi A, Hall KS, et al: Incidence of dementia and Alzheimer disease in two communities. JAMA 2001; 285: 739-747.

Hermsdorff HHM, Puchau B, Bressan J. Vitamin C and fibre consumption from fruits and vegetables improves oxidative stress markers in healthy young adults. Br J Nutr 2012; 107: 1119–1127.

Heroux M, Raghavendra Rao VL, Lavoie J, Richardson JS, Butterworth RF. Alterations of thiamine phosphorylation and of thiamine-dependent enzymes in Alzheimer’s disease. Metab Brain Dis. 1996; 11: 81-88.

Hershey AD, Powers SW, Vockell AL, Lecates SL, Ellinor PL, Segers A, Burdine D, Manning P, Kabbouche MA. Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine. Headache. 2007; 47: 73-80.

Higgins JP, Flicker L. Lecithin for dementia and cognitive impairment. Cochrane Database Syst Rev. 2003; (3): CD001015.

Hintikka J, Tolmunen T, Honkalampi K, et al: Daily tea drinking is associated with a low level of depressive symptoms in the Finnish general population. Eur J Epidemiol 2005; 20: 359-363.

Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E; Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012; 78: 1346-53.

Holtzman DM, Fagan AM, Mackey B, Tenkova T, Sartorius L, Paul SM, Bales K, Ashe KH, Irizarry MC, Hyman BT. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer’s disease model. Ann Neurol. 2000; 47: 739-47.

Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. Am Heart J. 2006; 151: 282-287.

Hoogendijk WJ, Lips P, Dik MG, et al: Depression is associated with decreased 25-hydroxyvitamin D and increased parathyroid hormone levels in older adults. Arch Gen Psychiatry 2008; 65: 508-512.

Hornstra G.: Essential fatty acids in mothers and their neonates. Am. J. Clin. Nutr. 2000; 71 Suppl. 5: 1262S–1269S.

Horrocks LA, Yeo YK: Health benefits of docosahexaenoic acid (DHA). Pharmacol. Res. 1999; 40: 211–225.

Hufschmidt A, Lücking CH. Neurologie compact: Für Klinik und Praxis. Georg Thieme Verlag, 2009, S. 394.

Hung YH, Bush AI, La Fontaine S. Links between copper and cholesterol in Alzheimer’s disease. Front Physiol. 2013; 4: 111.

Hurot JM, Cucherat M, Haugh M, Fouque D. Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review. J Am Soc Nephrol. 2002; 13: 708-714.

Imbard A, Benoist JF, Blom HJ. Neural tube defects, folic Acid and methylation. Int J Environ Res Public Health. 2013; 10: 4352-89.

Isobe C, Abe T, Terayama Y. Levels of reduced and oxidized coenzyme Q-10 and 8-hydroxy-2′-deoxyguanosine in the cerebrospinal fluid of patients with living Parkinson’s disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodegenerative process. Neurosci Lett. 2010; 469: 159-63.

Jacka FN, Pasco JA, Mykletun A, et al: Association of Western and traditional diets with depression and anxiety in women. Am J Psychiatry 2010; 167: 305-311.

Jain SK, McVie R, Jaramillo JJ, Palmer M, Smith T. Effect of modest vitamin E supplementation on blood glycated hemoglobin and triglyceride levels and red cell indices in type I diabetic patients. J Am Coll Nutr. 1996; 15: 458-461.

Jamilian H, Bagherzadeh K, Nazeri Z, Hassanijirdehi M: Vitamin D, parathyroid hormone, serum calcium and phosphorus in patients with schizophrenia and major depression. Int J Psychiatry Clin Pract 2013; 17: 30–34.

Jarisch R, Wandtke F: Wine and headache. Internat Arch Allergy Immunol 1996; 110: 7–12.

Josey BJ, Inks ES, Wen X, Chou CJ. Structure-activity relationship study of vitamin k derivatives yields highly potent neuroprotective agents. J Med Chem. 2013; 56: 1007-22.

Joy CB, Mumby-Croft R, Joy LA. Polyunsatu­rated fatty acid supplementation for schizophre­nia. Cochrane Database Syst Rev 2006; 19: CD001257.

Kalantar-Zadeh K, Kopple JD. Trace elements and vitamins in maintenance dialysis patients. Adv Ren Replace Ther 2003; 10: 170–182.

Kalyani RR, Stein B, Valiyil R, et al: Vitamin D treatment for the prevention of falls in older adults: systematic review and meta-analysis. J Am Geriatr Soc 2010; 58: 1299-1310.

Kawicka A, Regulska-Ilow B. How nutritional status, diet and dietary supplements can affect autism. A review. Rocz Panstw Zakl Hig. 2013; 64: 1-12.

Kazmi WH, Obrador GT, Sternberg M, et al. Carnitine therapy is associated with decreased hospital utilization among hemodialysis patients. Am J Nephrol. 2005; 25: 106-115.

Ke Y, Ming Qian Z. Iron misregulation in the brain: A primary cause of neurodegenerative disorders. Lancet Neurol 2003; 2: 246–253.

Kelley BJ, Knopman DS. Alternative medicine and Alzheimer disease. Neurologist. 2008; 14: 299-306.

Kempser PA, Wahlqvist ML: Dietary factors in the management of Parkinson’s disease. Nutr Rev 1994; 52: 51–58.

Kien CL, Ganther HE. Manifestations of chronic selenium deficiency in a child receiving total parenteral nutrition. Am J Clin Nutr 1983; 37: 319–328.

Kontush K, Schekatolina S. Vitamin E in neurodegenerative disorders: Alzheimer’s disease. Ann N Y Acad Sci. 2004; 1031: 249-262.

Kornberg A, Segal R, Theitler J, Yona R, Kaufman S. Folic acid deficiency, megaloblastic anemia and peripheral polyneuropathy due to oral contraceptives. Isr J Med Sci. 1989; 25: 142-5.

Krietsch K, Christensen L, White B: Prevalence, presenting symptoms, and psychological characteristics of individuals experiencing a diet-related mood-disturbance. Behav Ther 1988; 19: 593-604.

Kruit MC, Launer LJ, Overbosch J, van Buchem MA, Ferrari MD. Iron accumulation in deep brain nuclei in migraine: a population-based magnetic resonance imaging study. Cephalalgia. 2009; 29: 351-9.

Kumar N. Acute and subacute encephalopathies: deficiency states (nutritional). Semin Neurol. 2011; 31: 169-83.

Laurin D, Foley DJ, Masaki KH, White LR, Launer LJ. Vitamin E and C supplements and risk of dementia. JAMA. 2002; 288: 2266-8.

Lauritzen L, Hoppe C, Staarup EM, Michaelsen KF: Maternal fish oil supplementation in lactation and growth during the first 2,5 years of life. Pediatr. Res. 2005; 58: 235–242.

Lee JY, Cole TB, Palmiter RD, Suh SW, Koh JY. Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc Natl Acad Sci USA 2002; 99: 7705–7710.

Lee MY, Choi EJ, Lee MK, Lee JJ. Epigallocatechin gallate attenuates L-DOPA-induced apoptosis in rat PC12 cells. Nutr Res Pract. 2013;7: 249-55.

Lees AJ, Hardy J, Revesz T. Parkinson’s disease. Lancet 2009; 373: 2055–2066.

Levi, S.: Increased energy expenditure in Parkinson’s disease. Brit. Med. J. 1990; 301: 1256–1257.

Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci. 2001; 21: 8370-8377.

Lindenbaum J, Healton EB, Savage DG, et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med 1988; 318: 1720.

Løken-Amsrud KI, Myhr KM, Bakke SJ, Beiske AG, Bjerve KS, Bjørnarå BT, Hovdal H, Lilleås F, Midgard R, Pedersen T, Benth JŠ, Torkildsen Ø, Wergeland S, Holmøy T. Alpha-tocopherol and MRI outcomes in multiple sclerosis–association and prediction. PLoS One. 2013; 8: e54417.

Lourida I, Soni M, Thompson-Coon J, Purandare N, Lang IA, Ukoumunne OC, Llewellyn DJ. Mediterranean diet, cognitive function, and dementia: a systematic review. Epidemiology. 2013; 24: 479-89.

Lovell MA, Xie C, Markesbery WR. Protection against amyloid beta peptide toxicity by zinc. Brain Res 1999; 823: 88–95.

Luchsinger JA, Mayeux R. Dietary factors and Alzheimer’s disease. Lancet Neurol 2004; 3: 579–587.

Luchsinger JA, Tang MX, Miller J, Green R, Mayeux R. Higher folate intake is related to lower risk of Alzheimer’s disease in the elderly. J Nutr Health Aging. 2008; 12: 648-50.

Luchsinger JA, Tang MX, Miller J, Green R, Mayeux R. Relation of higher folate intake to lower risk of Alzheimer disease in the elderly. Arch Neurol. 2007; 64: 86-92.

Lu’o’ng Kv, Nguy Ecirctilde N LT. Role of thiamine in Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2011; 26: 588-98.

Lu’o’ng KV, Nguyên LT. The beneficial role of vitamin D in Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2011; 26: 511-20.

Madenci G, Bilen S, Arli B, Saka M, Ak F. Serum iron, vitamin B12 and folic acid levels in Parkinson’s disease. Neurochem Res. 2012;37:1436-41.

Maes M, Smith R, Christophe A, et al: Fatty acid composition in major depression: decreased omega 3 fractions in cholesteryl esters and increased C20:4 omega 6/C20:5 omega 3 ratio in cholesteryl esters and phospholipids. J Affect Disord 1996; 38: 35-46.

Mahadik SP, Pillai A, Joshi S, Foster A. Pre­vention of oxidative stress-mediated neuropatho­logy and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia. Int Rev Psychiatry 2006; 18: 119–131.

Maier W, Rietschel M, Lichtermann D et al. Family and genetic studies on the relationship of schizophrenia to affective disorders. Eur Arch Psychiatry Clin Neurosci 1999; 249(Suppl 4): 57–61.

Markley HG. CoEnzyme Q10 and riboflavin: the mitochondrial connection. Headache. 2012;52 Suppl 2: 81-7.

Martínez-Lapiscina EH, Clavero P, Toledo E, Estruch R, Salas-Salvadó J, San Julián B, Sanchez-Tainta A, Ros E, Valls-Pedret C, Martinez-Gonzalez MA. Mediterranean diet improves cognition: the PREDIMED-NAVARRA randomised trial. J Neurol Neurosurg Psychiatry. 2013 May 13.

Masaki KH, Losonczy KG, Izmirlian G, et al. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology. 2000; 54: 1265-1272.

Mastrogiacoma F, Bettendorff L, Grisar T, Kish SJ. Brain thiamine, its phosphate esters, and its metabolizing enzymes in Alzheimer’s disease. Ann Neurol. 1996; 39: 585-591.

Masud T. Trace elements and vitamins in renal disease. In: Mitch WE, Klahr S (eds) Handbook of nutrition and the kidney. Lippincott Williams & Wilkins, Philadelphia, 2005; S. 196–217.

Matthews KL, Chen CP, Esiri MM, Keene J, Minger SL, Francis PT. Noradrenergic changes, aggressive behavior, and cognition in patients with dementia. Biol Psychiatry. 2002 1; 51: 407-16.

Mauskop A, Varughese J. Why all migraine patients should be treated with magnesium. J Neural Transm. 2012; 119: 575-9.

May JM. Vitamin C transport and its role in the central nervous system. Subcell Biochem. 2012; 56: 85-103.

McCaddon A. Vitamin B12 in neurology and ageing; clinical and genetic aspects. Biochimie. 2013; 95: 1066-76.

McGrath J, Eyles D, Mowry B, Yolken R, Buka S: Low maternal vitamin D as a risk factor for schizophrenia: a pilot study using banked sera. Schizophr Res, 2003; 63: 73–78.

McGrath J, Saari K, Hakko H, Jokelainen J, Jones P, Järvelin MR, Chant D, Isohanni M: Vitamin D supplementation during the first year of life and risk of schizophrenia: a Finnish birth cohort study. Schizophr Res 2004; 67: 237–245.

McMahon JA, Green TJ, Skeaff CM, Knight RG, Mann JI, Williams SM. A controlled trial of homocysteine lowering and cognitive performance. N Engl J Med. 2006; 354: 2764-2772.

McNamara RK, Able J, Jandacek R, et al. Docosahexaenoic acid supplementation increases prefrontal cortex activation during sustained attention in healthy boys: a placebo-controlled, dose-ranging, functional magnetic resonance imaging study. Am J Clin Nutr. 2010; 91: 1060–1067.

Meamar R, Maracy M, Chitsaz A, Ghazvini MR, Izadi M, Tanhaei AP. Association between serum biochemical levels, related to bone metabolism and Parkinson’s disease. J Res Med Sci. 2013; 18: S39-42.

Melse-Boonstra A, Jaiswal N. Iodine deficiency in pregnancy, infancy and childhood and its consequences for brain development. Best Pract Res Clin Endocrinol Metab. 2010; 24: 29–38.

Mesulam M. The cholinergic lesion of Alzheimer’s disease: pivotal factor or side show? Learn Mem. 2004; 11: 43-9.

Mielke MM, Lyketsos CG. Lipids and the pathogenesis of Alzheimer’s disease: is there a link? Int Rev Psychiatry. 2006; 18: 173-86.

Miyake Y, Fukushima W, Tanaka K, Sasaki S, Kiyohara C, Tsuboi Y, Yamada T, Oeda T, Miki T, Kawamura N, Sakae N, Fukuyama H, Hirota Y, Nagai M; Fukuoka KinkinParkinson’s Disease Study Group. Dietary intake of antioxidant vitamins and risk of Parkinson’s disease: a case-control study in Japan. Eur J Neurol. 2011; 18:106-13.

Mochizuki H, Yasuda T. Iron Accumulation in Parkinson’s disease. J Neural Transm 2012; 119: 1511-1514.

Morris MC, Evans DA, Bienias JL, et al. Dietary folate and vitamin B12 intake and cognitive decline among community-dwelling older persons. Arch Neurol. 2005; 62: 641-645.

Morris MC, Evans DA, Schneider JA, Tangney CC, Bienias JL, Aggarwal NT. Dietary folate and vitamins B-12 and B-6 not associated with incident Alzheimer’s disease. J Alzheimers Dis. 2006; 9: 435-443.

Morris MS. The role of B vitamins in preventing and treating cognitive impairment and decline. Adv Nutr. 2012; 3: 801-12.

Müller T, Jugel C, Muhlack S, Klostermann F. Methyl group-donating vitamins elevate 3-O-methyldopa in patients with Parkinson disease. Clin Neuropharmacol. 2013; 36: 52-4.

Munger KL, Levin LJ, Hollis BW, Howard NS, Ascherio A: Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006; 20: 2832–2837.

Myers GJ, Thurston SW, Pearson AT, et al. Postnatal exposure to methyl mercury from fish consumption: a review and new data from the Seychelles Child Development Study. Neurotoxicology. 2009; 30:338–349.

Myint PK, Luben RN, Welch AA, Bingham SA, Wareham NJ, Khaw KT. Plasma vitamin C concentrations predict risk of incident stroke over 10 y in 20 649 participants of the European Prospective Investigation into Cancer Norfolk prospective population study. Am J Clin Nutr. 2008; 87:64-69.

Naarding P, Kremer HP, Zitman FG. Huntington’s disease: a review of the literature on prevalence and treatment of neuropsychiatric phenomena. Eur Psychiatry 2001; 16: 439-45.

Nachum-Biala Y, Troen AM. B-vitamins for neuroprotection: narrowing the evidence gap. Biofactors. 2012; 38: 145-50.

Nelson C, Wengreen HJ, Munger RG, Corcoran CD. Dietary folate, vitamin B-12, vitamin B-6 and incident Alzheimer’s disease: the cache county memory, health and aging study. J Nutr Health Aging. 2009; 13: 899-905.

Nemets B, Stahl Z, Belmaker RH: Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 2002; 159: 477-479.

Nemets H, Nemets B, Apter A et al. Ome­ga-3 treatment of childhood depression: a control­led, double-blind pilot study. Am J Psychiatry 2006; 163: 1098–1100.

Newcomer JW. Metabolic risk during antip­sychotic treatment. Clin Ther 2004; 26: 1936–1946.

Northstone K, Emmett PM. Are dietary patterns stable throughout early and mid-childhood? A birth cohort study. Br J Nutr. 2008; 100: 1069–1076.

Nourhashemi F, Gillette-Guyonnet S, Andrieu S, et al. Alzheimer disease: protective factors. Am J Clin Nutr. 2000; 71: 643S-649S.

Nye C, Brice A: Combined vitamin B6-magnesium treatment in autism spectrum disorder. Cochrane Database Syst Rev 2002.CD003497

O’Brien HL, Hershey AD. Vitamins and paediatric migraine: Riboflavin as a preventative medication. Cephalalgia. 2010; 30: 1417-8.

Orsucci D, Mancuso M, Ienco EC, LoGerfo A, Siciliano G. Targeting mitochondrial dysfunction and neurodegeneration by means of coenzyme Q10 and its analogues. Curr Med Chem. 2011; 18: 4053-64.

Oudshoorn C, Mattace-Raso FU, van der Velde N, Colin EM, van der Cammen TJ. Higher serum vitamin D3 levels are associated with better cognitive test performance in patients with Alzheimer’s disease. Dement Geriatr Cogn Disord. 2008; 25: 539-43.

Ozcan ME, Gulec M, Ozerol E et al. Antio­xidant enzyme activities and oxidative stress in af­fective disorders. Int Clin Psychopharmacol 2004; 19: 89–95.

Pan R, Qiu S, Lu DX, Dong J. Curcumin improves learning and memory ability and its neuroprotective mechanism in mice. Chin Med J (Engl). 2008; 121: 832-839.

Pardutz A, Vecsei L. Should magnesium be given to every migraineur? No. J Neural Transm. 2012; 119: 581-5.

Pareyson D., Solari A. Charcot–Marie–Tooth disease type 1A: is ascorbic acid effective? Lancet Neurology. 2009; 8: 1075–1077.

Parker G, Gibson NA, Brotchie H et al. Omega-3 fatty acids and mood disorders. Am J Psychiatry 2006; 163: 969–978.

Parker JA, Arango M, Abderrahmane S, Lambert E, Tourette C, Catoire H, Neri C. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat. Genet. 2005; 37, 349–350.

Parkinson Study Group: Impact of deprenyl and tocopherol treatment on Parkinson’s disease in TATATOP subjects not requiring levodopa. Ann Neurol 1996; 39: 29–36.

Passage E., Norreel J.C., Noack-Fraissignes P., Sanguedolce V., Pizant J., Thirion X. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot–Marie–Tooth disease. Nature Medicine. 2004; 10: 396–401.

Peet M, Glen I, Horrobin DF (eds). Phos­pholipid spectrum disorders in psychiatry and neurology. Marius Press, Carnforth, Lancashire, 2003.

Peet M, Horrobin DF: A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 2002; 59: 913-919.

Peet M, Stokes C. Omega-3 Fatty acids in the treatment of psychiatric disorders. Drugs 2005; 65: 1051–1059.

Peet M. International variations in the out­come of schizophrenia and the prevalence of de­pression in relation to national dietary practices: an ecological analysis. Br J Psychiatry 2004; 184: 404–408.

Peet M. Nutrition and schizophrenia: an epidemiological and clinical perspective. Nutr Health 2003; 17: 211–219.

Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol 2009; 8: 1006–1018.

Perez L, Heim L, Sherzai A, Jaceldo-Siegl K, Sherzai A. Nutrition and vascular dementia. J Nutr Health Aging. 2012; 16: 319-24.

Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005; 352: 2379-2388.

Peterson AL, Mancini M, Horak FB. The relationship between balance control and vitamin D in Parkinson’s disease-a pilot study. Mov Disord. 2013; 28: 1133-7.

Pettegrew JW, Klunk WE, Panchalingam K, et al. Clinical and neurochemical effects of acetyl-L- carnitine in Alzheimer’s disease. Neurobiol Aging 1995; 16:1-4.

Phillips RJ, Walter GC, Wilder SL et al. Alpha-synuclein-immunopositive myenteric neurons and vagal preganglionic terminals: autonomic pathway implicated in Parkinson’s disease? Neuroscience 2008; 153: 733–750.

Pinero DJ, Hu J, Connor JR. Alterations in the interaction between iron regulatory proteins and their iron-responsive element in normal and Alzheimer’s diseased brains. Cell Mol Biol (Noisy-le-grand). 2000; 46: 761-776.

Potocnik FC, van Rensburg SJ, Park C, Taljaard JJ, Emsley RA: Zinc and platelet membrane microviscosity in Alzheimer’s disease. The in vivo effect of zinc on platelet membranes and cognition. S Afr Med J 1997; 87: 1116–1119.

Psychrembel. Klinisches Wörterbuch. Walter de Gruyter & Co. Verlag, Berlin. 1997, 258. Auflage.

Puglielli L, Tanzi RE, Kovacs DM. Alzheimer’s disease: the cholesterol connection. Nat Neurosci. 2003; 6: 345-51.

Quarrell O, Harper P. The clinical neurology of Huntington’s disease. Huntington’s disease. P. S. Harper. London, Saunders: S.31-72, 1996.

Quinn JF, Raman R, Thomas RG, et al: Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA 2010; 304: 1903-1911.

Ramaekers VT, Calomme M, Vanden Berghe D, Makropoulos W. Selenium deficiency triggering intractable seizures. Neuropediatrics 1994; 25: 217–223.

Rao AV, Balachandran B. Role of oxidative stress and antioxidants in neurodegenerative di­seases. Nutr Neurosci 2002; 5: 291–309.

Ravaglia G, Forti P, Maioli F, et al. Homocysteine and folate as risk factors for dementia and Alzheimer disease. Am J Clin Nutr. 2005; 82: 636-643.

Reddy RD, Keshavan MS, Yao JK. Redu­ced red blood cell membrane essential polyunsa­turated fatty acids in first episode schizophrenia at neuroleptic-naive baseline. Schizophr Bull 2004; 30: 901–911.

Reddy Vanga S, Good M, Howard PA, Vacek JL: Role of vitamin D in cardiovascular health. Am J Cardiol 2010; 106: 798-805.

Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, Sambamurti K, Duff K, Pappolla MA. Hypercholesterolemia accelerates the Alzheimer’s amyloid pathology in a transgenic mouse model. Neurobiol Dis. 2000; 7: 321-31.

Rieder MJ. Prevention of neural tube defects with periconceptional folic acid. Clinn Perinatol 1994; 21: 483–503.

Riggs KM, Spiro A, 3rd, Tucker K, Rush D. Relations of vitamin B-12, vitamin B-6, folate, and homocysteine to cognitive performance in the Normative Aging Study. Am J Clin Nutr. 1996;63: 306-314.

Rimland B, Callaway E, Dreyfus P: The effects of high doses of vitamin B6 on autistic children: a double-blind crossover study. Am J Psychiatry 1978; 135:472-475.

Rimland B: Critique of “Efficacy of vitamin B6 and magnesium in the treatment of autism”. J Autism Dev Disord 1998; 28: 580-581.

Rimland B: High-dose vitamin B6 and magnesium in treating autism: response to study by Findling et al. J Autism Dev Disord 1998; 28: 581-582.

Rodriguez-Martin JL, Qizilbash N, Lopez-Arrieta JM. Thiamine for Alzheimer’s disease (Cochrane Review). Cochrane Database Syst Rev. 2001; 2: CD001498.

Roman GC, Erkinjuntti T, Wallin A et al. Subcortical ischaemic vascular dementia. Lancet Neurol 2002; 1: 426–436.

Roman GC, Kalaria RN. Vascular determinants of cholinergic deficits in Alzheimer disease and vascular dementia. Neurobiol Aging 2006; 27: 1769–1785.

Ruitenberg A, van Swieten JC, Witteman JCM, Metha KM, van Duijn CM, Hofman A, Breteler MMB: Alcohol consumption and risk of dementia: the Rotterdam Study. Lancet 2000; 359: 281–286.

Russel MR, Suter P. Vitamin and trace mineral deficiency and excess. In: Fauci AS, Kasper D, Longo D, Braunwald E (eds) Harrison’s principles of internal medicine. McGraw-Hill, New York, 2008.

Ryan AS, Astwood JD, Gautier S, et al. Effects of long-chain polyunsaturated fatty acid supplementation on neurodevelopment in childhood: a review of human studies. Prostaglandins Leukot Essent Fatty Acids. 2010; 82: 305–314.

Sánchez-Villegas A, Delgado-Rodríguez M, Alonso A, et al: Association of the Mediterranean dietary pattern with the incidence of depression: the Seguimiento Universidad de Navarra/University of Navarra follow-up (SUN) cohort. Arch Gen Psychiatry 2009; 66: 1090-1098.

Sandor PS, Afra J, Ambrosini A, Schoenen J. Prophylactic treatment of migraine with beta-blockers and riboflavin: differential effects on the intensity dependence of auditory evoked cortical potentials. Headache. 2000; 40: 30–35.

Saperstein DS, Wolfe GI, Gronseth GS, Nations SP, Herbelin LL, Bryan WW, Barohn RJ. Challenges in the identification of cobalamin-deficiency polyneuropathy. Arch Neurol. 2003; 60: 1296-301.

Sarris J, Schoendorfer N, Kavanagh DJ: Major depressive disorder and nutritional medicine: a review of monotherapies and adjuvant treatments. Nutr Rev 2009; 67: 125-131.

Satterfield G, Anderson J, Moore C. Evidence supporting the incorporation of the dietary approaches to stop hypertension (DASH) eating pattern into stroke self-management programs: a review. J Neurosci Nurs. 2012; 44: 244-50.

Sayre LM, Perry G, Atwood CS, Smith MA. The role of metals in neurodegenerative diseases. Cell Mol Biol. 2000; 46: 731-741.

Sayre LM, Perry G, Smith MA. Redox metals and neurodegenerative disease. Curr Opin Chem Biol 1999; 3: 220–225.

Scalabrino G, Veber D, Briani C, Milani S, Terralavoro A, Brenna S, Valenti L, Silani V, Morelli C, Peracchi M. Cobalamin as a regulator of serum and cerebrospinal fluid levels of normal prions. J Clin Neurosci. 2013; 20: 134-8.

Scarmeas N, Luchsinger JA, Stern Y, Gu Y, He J, DeCarli C, Brown T, Brickman AM. Mediterranean diet and magnetic resonance imaging-assessed cerebrovascular disease. Ann Neurol. 2011; 69: 257-68.

Scarmeas N, Stern Y, Tang MX et al. Mediter­ranean diet and risk for Alzheimer’s disease. Ann Neurol 2006; 59: 912–921.

Scheider WL, Hershey LA, Vena JE, Holmlund T, et al: Dietary antioxidants and other dietary factors in the etiology of Parkinson’s disease. Movement Disorders 1997; 12: 190–196.

Schilling G, Coonfield ML, Ross CA, Borchelt DR. Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington’s disease transgenic mouse model. Neurosci Lett 2001; 315, 149–153.

Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis: a randomized controlled trial. Neurology. 1998; 50: 466–470.

Scopp AL: MSG and hydrolyzed vegetable protein induced headache: Review and case studies. Headache 1991; 31: 107–110.

Sechi G, Serra A. Wernicke’s encephalopathy: new clinical settings and recent advances in diagnosis and management. Lancet Neurol 2007; 6: 442–455.

Selhub J, Bagley LC, Miller J, Rosenberg IH. B vitamins, homocysteine, and neurocognitive function in the elderly. Am J Clin Nutr. 2000; 71: 614S-620S.

Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Engl J Med. 2002; 346: 476-483.

Sesso HD, Buring JE, Christen WG, et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians’ Health Study II randomized controlled trial. JAMA. 2008; 300: 2123-2133.

Severus WE, Littman AB, Stoll AL. Omega-3 fatty acids, homocysteine, and the increased risk of cardiovascular mortality in major depressive disorder. Harv Rev Psychiatry 2001; 9: 280–293.

Shahbeigi S, Pakdaman H, Fereshtehnejad SM, Nikravesh E, Mirabi N, Jalilzadeh G. Vitamin d3 concentration correlates with the severity of multiple sclerosis. Int J Prev Med. 2013; 4: 585-91.

Sharma B, Singh N. Salutary effect of NFκB inhibitor and folacin in hyperhomocysteinemia-hyperlipidemia induced vascular dementia. Prog Neuropsychopharmacol Biol Psychiatry. 2012; 38: 207-15.

Shaw K, Turner J, Del Mar C. Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database Syst Rev 2002; (1): CD003198.

Shobab LA, Hsiung GY, Feldman HH. Cholesterol in Alzheimer’s disease. Lancet Neurol. 2005; 205; 4: 841-52.

Shoulson J: The Parkinson study group, effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. New Engl J Med 1993; 328 176–183.

Shults CW, Haas RH, Passov D, Beal MF. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann Neurol. 1997; 42(2): 261-264.

Shurtleff DB, Lemire RJ. Epidemiology, etiologic factors and prenatal diagnosis of open spinal dysraphism. Neurosurg Clin North Am 1995; 6: 183–193.

Sjogren M, Mielke M, Gustafson D, Zandi P, Skoog I. Cholesterol and Alzheimer’s disease—is there a relation? Mech Ageing Dev. 2006; 127: 138-47.

Smith AL, Fredlund R: The protective effects of physical exercise on the development of Alzheimer’s disease. Neurology 1998; 50: A89-A90.

Smolders J, Damoiseaux J, Menheere P, Hupperts R: Vitamin D as an immune modulator in multiple sclerosis, a review. J Neuroimmunol 2008; 194: 7–17.

Snowdon DA, Tully CL, Smith CD, Riley KP, Markesbery WR. Serum folate and the severity of atrophy of the neocortex in Alzheimer disease: findings from the Nun study. Am J Clin Nutr. 2000; 71: 993-998.

Solfrizzi V, Frisardi V, Seripa D, Logroscino G, Imbimbo BP, D’Onofrio G, Addante F, Sancarlo D, Cascavilla L, Pilotto A, Panza F. Mediterranean diet in predementia and dementia syndromes. Curr Alzheimer Res. 2011; 8: 520-42.

Stefan Schwarz, Hans Leweling, Michael Daffertshofer, Hans-Michael Meinck: Unkonventionelle Therapien der multiplen Sklerose: Nutzen unklar. Deutsches Ärzteblatt. 2005; 102: 2102-2107.

Stevens T, Livingston G, Kitchen G et al. Islington study of dementia subtypes in the community. Br J Psychiatry 2002; 180: 270–276.

Stoye D, Schubert C, Goihl A, Guttek K, Reinhold A, Brocke S, Grüngreiff K, Reinhold D. Zinc aspartate suppresses T cell activation in vitro and relapsing experimental autoimmune encephalomyelitis in SJL/J mice. Biometals. 2012; 25: 529-39.

Su KP, Huang SY, Chiu CC, Shen WW. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol. 2003; 13: 267-71.

Su KP, Huang SY, Chiu TH, et al: Omega-3 fatty acids for major depressive disorder during pregnancy: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008; 69: 644-651.

Sullivan LE, Fiellin DA, O’Connor PG: The prevalence and impact of alcohol problems in major depression: a systematic review. Am J Med 2005; 118: 330-341.

Sun Y, Lu CJ, Chien KL, Chen ST, Chen RC. Efficacy of multivitamin supplementation containing vitamins B6 and B12 and folic acid as adjunctive treatment with a cholinesterase inhibitor in Alzheimer’s disease: a 26-week, randomized, double-blind, placebo-controlled study in Taiwanese patients. Clin Ther. 2007; 29: 2204-14.

Sun-Edelstein C, Mauskop A. Foods and supplements in the management of migraine headaches. Clin J Pain. 2009; 25: 446-52.

Swank, RL, Dugan BB: Effect of low saturated fat diet on early and late cases of multiple sclerosis. Lancet 1990; 336: 37–39.

Tabrizi SJ, Blamire AM, Manners DN, Rajagopalan B, Styles P, Schapira AH, Warner TT. Creatine therapy for Huntington’s disease: clinical and MRS findings in a 1-year pilot study. Neurology 2003; 61, 141–142.

Tarighat Esfanjani A, Mahdavi R, Ebrahimi Mameghani M, Talebi M, Nikniaz Z, Safaiyan A. The effects of magnesium, L-carnitine, and concurrent magnesium-L-carnitine supplementation in migraine prophylaxis. Biol Trace Elem Res. 2012; 150: 42-8.

Taylor MJ, Carney S, Geddes J, Goodwin G. Folate for depressive disorders. Cochrane Databa­se Syst Rev2003; (2): CD003390.

Taylor MJ, Wilder H, Bhagwagar Z, Geddes J. Inositol for depressive disorders. Cochrane Databa­se Syst Rev 2004; (2): CD004049.

Tejani AM, Wasdell M, Spiwak R, Rowell G, Nathwani S. Carnitine for fatigue in multiple sclerosis. Cochrane Database Syst Rev. 2012 May 16; 5: CD007280.

Tepper SJ. Complementary and alternative treatments for childhood headaches. Curr Pain Headache Rep. 2008; 12: 379-83.

Tezvergil-Mutluay A, Carvalho RM, Pashley DH. Hyperzincemia from ingestion of denture adhesives. J Prosthet Dent. 2010; 103: 380-3.

Thompson KJ, Shoham S, Connor JR. Iron and neurodegenerative disorders. Brain Res Bull 2001; 55:155–164.

Tiemeier H, Tuijl HR van, Hofman A et al. Vit­amin B12, folate, and homocysteine in depression: the Rotterdam Study. Am J Psychiatry 2002; 159: 2099–2101.

Tiemeier H, van Tuijl HR, Hofman A, et al: Plasma fatty acid composition and depression are associated in the elderly: the Rotterdam Study. Am J Clin Nutr 2003; 78: 40-46.

Todorich BM, Connor JR. Redox metals in Alzheimer’s disease. Ann NY Acad Sci 2004; 1012: 171–178.

Török R, Török N, Szalardy L, Plangar I, Szolnoki Z, Somogyvari F, Vecsei L, Klivenyi P. Association of vitamin D receptor gene polymorphisms and Parkinson’s disease in Hungarians. Neurosci Lett. 2013; 551: 70-4.

Towbin A, Inge TH, Garcia VF, et al. Beriberi after gastric bypass surgery in adolescence. J Pediatr 2004; 145: 263.

Tully A, Roche H, Doyle R, Fallon C, Bruce I, Lawlor B. Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer’s disease: a case-control study. Br J Nutr 2003; 89: 483–489.

Tzourio C, Anderson C, Chapman N et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with ce¬rebrovascular disease. Arch Intern Med 2003; 163: 1069–1075.

Van Dam F, Van Gool WA. Hyperhomocysteinemia and Alzheimer’s disease: A systematic review. Arch Gerontol Geriatr. 2009; 48: 425-30.

Van de Rest O, Geleijnse JM, Kok FJ et al. Effect of fish oil on cognitive performance in older subjects: a randomized controlled trial. Neurology 2008; 71(6): 430–438.

van Rensburg SJ, Kotze MJ, van Toorn R. The conundrum of iron in multiple sclerosis–time for an individualised approach. Metab Brain Dis. 2012; 27: 239-53.

Verbessem P, Lemiere J, Eijnde BO, Swinnen S, Vanhees L, Van Leemputte M, Hespel P, Dom R: Creatine supplementation in Huntington’s disease: a placebo- controlled pilot trial. Neurology 2003; 61, 925–930.

Verdery R, Walford R: Caloric restriction in Biosphere II: effects of energy restriction on lipid and lipoprotein levels and HDL subfractions. Paper presented at the Annual Meeting of the American Aging Association, Los Angeles, 1996. 37 (abstract no. 75)

Vesela E, Racek J, Trefil L, Jankovy’ch V, Pojer M. Effect of L-carnitine supplementation in hemodialysis patients. Nephron. 2001; 88: 218-223.

Visser EJ. Is migraine a complex regional pain syndrome of the brain? Migraine prophylaxis with vitamin C? Pain Pract. 2011; 11: 199-200.

Vos M, Esposito G, Edirisinghe JN, Vilain S, Haddad DM, Slabbaert JR, Van Meensel S, Schaap O, De Strooper B, Meganathan R, Morais VA, Verstreken P. Vitamin K2 is a mitochondrial electron carrier that rescues pink1 deficiency. Science. 2012; 336: 1306-10.

Waggoner DJ, Bartnikas TB, Gitlin JD. The role of copper in neurodegenerative disease. Neurobiol Dis 1999; 6: 221–230.

Wang HX, Wahlin A, Basun H, Fastbom J, Winblad B, Fratiglioni L. Vitamin B(12) and folate in relation to the development of Alzheimer’s disease. Neurology. 2001; 56:1188-1194.

Waschbisch A, Wenny I, Tallner A, Schwab S, Pfeifer K, Mäurer M: Physical activity in multiple sclerosis: a comparative study of vitamin D, brain-derived neurotrophic factor and regulatory T cell populations. Eur Neurol 2012; 68: 122–128.

Weir DG, Molloy AM. Microvascular disease and dementia in the elderly: are they related to hyperhomocysteinemia? Am J Clin Nutr. 2000; 71: 859-860.

Welch KM. Iron in the migraine brain; a resilient hypothesis. Cephalalgia. 2009; 29: 283-5.

Werlin SL, Harb JM, Swick H, Blank E. Neuromuscular dysfunction and ultrastructural pathology in children with chronic cholestasis and vitamin E deficiency. Ann Neurol 1983; 13: 291.

Westover AN, Marangell LB: A cross-national relationship between sugar consumption and major depression? Depress Anxiety 2002; 16: 118-120.

Whitehouse PJ. The cholinergic deficit in Alzheimer’s disease. J Clin Psychiatry 1998;59 (Suppl 13): 19-22.

Whitmer RA, Gunderson EP, Barrett-Connor E et al. Obesity in middle age and future risk of dementia: a 27 year longitudinal population ba­sed study. BMJ 2005; 330: 1360.

Willcox BJ. Caloric restriction, the traditio­nal Okinawan diet, and healthy aging: the diet of the world’s longest-lived people and its poten­tial impact on morbidity and life span. Ann N Y Acad Sci S 2007; 1114: 434–455.

Williams AL, Cotter A, Sabina A, et al: The role for vitamin B-6 as treatment for depression: a systematic review. Fam Pract 2005; 22: 532-537.

Witte AV, Fobker M, Gellner R et al. Caloric restriction improves memory in elderly humans. Proc Natl Acad Sci U S A 2009; 106: 1255–1260.

Wolozin B, Kellman W, Rousseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol.2000; 57: 1439-43.

Xaplanteris P, Vlachopoulos C, Pietri P, Terentes Printzios D, Kardara D. Tomato paste supplementation improves endothelial dynamics and reduces plasma total oxidative status in healthy subjects. Nutr Res 2012; 32: 390–394.

Yang F, Lim GP, Begum AN, et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem. 2005; 280: 5892-5901.

Yao JK, Leonard S, Reddy RD. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr Res 2000; 42: 7–17.

Yokoyama T, Date C, Kokubo Y, Yoshiike N, Matsumura Y, Tanaka H. Serum vitamin C concentration was inversely associated with subsequent 20-year incidence of stroke in a Japanese rural community. The Shibata study. Stroke. 2000; 31: 2287-2294.

Zaman Z, Roche S, Fielden P, Frost PG, Niriella DC, Cayley ACD: Plasma concentrations of vitamins A and E and carotenoids in Alzheimer’s disease. Age and Ageing 1992; 21: 91–94.

Zandi PP, Anthony JC, Khachaturian AS, et al: Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: The Cache County Study. Arch. Neurol. 2004; 61: 82–88.

Zarros ACh, Kalopita KS, Tsakiris ST. Serotoninergic impairment and aggressive behavior in Alzheimer’s disease. Acta Neurobiol Exp (Wars).2005; 65: 277-86.

Zhang J, Hebert JR, Muldoon MF. Dietary fat intake is associated with psychosocial and cognitive functioning of school-aged children in the United States. J Nutr. 2005; 135: 1967–1973.

Zhang XY, Tan YL, Cao LY et al. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr Res 2006; 81: 291–300.

Zhuo JM, Praticò D. Acceleration of brain amyloidosis in an Alzheimer’s disease mouse model by a folate, vitamin B6 and B12-deficient diet. Exp Gerontol. 2010; 45: 195-201.

Ziaei S, Kazemnejad A, Sedighi A. The effect of vitamin E on the treatment of menstrual migraine. Med Sci Monit. 2009; 15: CR16-9.

Pharmabrain Logo

European Union Trademark no. 006894216
US Patent and Trademark Office reg. no. 3,705,613
International Registration 1460744
All rights reserved.

Wir sind Pharmabrain.

Pharmabrain GmbH – Wir trainieren Ihren Erfolg
Gesundheitskommunikation, Teamentwicklung, Projektmanagement


Wissenschaftliche Exzellenz, praktische Orientierung, Implementierung


Unsere Enterprise Lösungen



Pharmabrain GmbH
Telefon: +49-30-28091515
E-Mail: support@pharmabrain.org

Research and Training Center

Schumannstr. 7b
D-10117 Berlin


Schumannstr. 7a
D-10117 Berlin